These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 1848627

  • 1. Influence of chronic lithium treatment upon the motivational effects of opioids: alteration in the effects of mu- but not kappa-opioid receptor ligands.
    Shippenberg TS, Herz A.
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1101-6. PubMed ID: 1848627
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Place-conditioning properties of mu, kappa, and sigma opioid agonists.
    Iwamoto ET.
    Alcohol Drug Res; 1991 Mar; 6(5):327-39. PubMed ID: 3011025
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tolerance and selective cross-tolerance to the motivational effects of opioids.
    Shippenberg TS, Emmett-Oglesby MW, Ayesta FJ, Herz A.
    Psychopharmacology (Berl); 1988 Mar; 96(1):110-5. PubMed ID: 3147470
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists.
    Shippenberg TS, Herz A.
    Brain Res; 1987 Dec 08; 436(1):169-72. PubMed ID: 2961413
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ, Doty P, Negus SS, Mattox SR, Dykstra LA.
    J Pharmacol Exp Ther; 1990 Jul 08; 254(1):13-22. PubMed ID: 2164087
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ, Członkowski A, Lipkowski A, Herz A.
    J Pharmacol Exp Ther; 1989 Oct 08; 251(1):342-50. PubMed ID: 2571723
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse.
    Horan PJ, de Costa BR, Rice K, Haaseth RC, Hruby VJ, Porreca F.
    J Pharmacol Exp Ther; 1993 Aug 08; 266(2):926-33. PubMed ID: 8394923
    [Abstract] [Full Text] [Related]

  • 18. Further study of kappa opioids on increased urination.
    Leander JD.
    J Pharmacol Exp Ther; 1983 Oct 08; 227(1):35-41. PubMed ID: 6137557
    [Abstract] [Full Text] [Related]

  • 19. Morphine-induced place preference in the CXBK mouse: characteristics of mu opioid receptor subtypes.
    Suzuki T, Funada M, Narita M, Misawa M, Nagase H.
    Brain Res; 1993 Jan 29; 602(1):45-52. PubMed ID: 8383571
    [Abstract] [Full Text] [Related]

  • 20. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.
    Mucha RF, Herz A.
    Psychopharmacology (Berl); 1985 Jan 29; 86(3):274-80. PubMed ID: 2994144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.